Filter by: patients
What is Arimidex?

ARIMIDEX is a brand name for anastrozole. It is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer. Read more...Click to read more below

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Breast Cancer 14 8 Efficacy_major Efficacy_moderate Efficacy_cant_tell
Increase effect of another treatment 3 0
Invasive Lobular Carcinoma 2 1 Efficacy_cant_tell
General health 1 0
Doctor recommendation 1 0
Other 1 0

See all 15 patients currently taking Arimidex

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
2
Moderate
2
Mild
2
None
3

Reported Dosages

  1 mg daily
  15 Number of Patients: 15  

Reported Stop Reasons

Why Patients Stopped Taking Arimidex (multiple reasons could be selected)
Reason # Patients Percentage of patients
Side effects too severe 3   Side effects too severe: 50%
Doctor's advice 2   Doctor's advice: 33%
Other 2   Other: 33%
Expense 1   Expense: 17%
Course of treatment ended 1   Course of treatment ended: 17%

See all 6 patients who’ve stopped taking Arimidex

Currently Taking Arimidex

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Arimidex

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Arimidex

Always
8 89%
Usually
1 11%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Arimidex

Very
0 0%
Somewhat
0 0%
A little
2 22%
Not at all
7 78%

Cost

Paid out of pocket

Cost of Arimidex

$200+
2 33%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
4 67%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 11, 2012.